$EVFM News

Evofem Biosciences Q1 EPS $(0.04), Sales $899.000K Up From $845.000K YoY

Evofem CEO Saundra Pelletier Calls for a "Ground-Up Reset" of Women’s Health at Fierce JPM Week 2026

Evofem Expands "Say Vagina" Campaign With Launch of Say Vagina Store

Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE

Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update

Evofem Biosciences Q3 EPS $(0.01) Up From $(0.02) YoY, Sales $4.952M Up From $4.496M YoY

Evofem Announces Voting Results from Special Meeting of Stockholders

Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates

Evofem Biosciences Honors World Contraception Day

Evofem Biosciences Sets September 26 Special Meeting For Expected Approval Of Merger With Aditxt

Evofem says FDA Orange Book lists patent for Solosec treatment

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Evofem Biosciences Q2 EPS $(0.02), Sales $4.825M Up From $4.160M YoY

Windtree Signs Deal With A Pharmaceutical Manufacturer In China To Cut PHEXXI Manufacturing Costs Over 50% By 2026; Evofem And Windtree Exploring Other Partnerships

Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1

Evofem Reports First Quarter 2025 Financial Results and Provides Business Update

Evofem Biosciences Q1 Sales $845.00K Down From $3.60M YoY

'FDA Commissioner Says 'no Plans' To Pull Abortion Pill Mifepristone' - Financial Times